

CLAIMS

1. An isolated Tau-binding antibody or binding fragment thereof, wherein said Tau-binding antibody or binding fragment thereof comprises
a light chain variable region comprising a CDR1 selected from SEQ ID No.: 1, a CDR2 selected from SEQ ID No.: 2, and a CDR3 selected from SEQ ID No.: 53; and
a heavy chain variable region comprising a CDR1 selected from SEQ ID No.: 4, a CDR2 selected from SEQ ID No.: 5, and a CDR3 selected from SEQ ID No.: 49.
2. An isolated Tau-binding antibody or binding fragment thereof, wherein said Tau-binding antibody or binding fragment thereof comprises
a light chain variable region comprising SEQ ID No.: 11, and
a heavy chain variable region comprising SEQ ID No.: 14.
3. A Tau-binding antibody or binding fragment thereof of any of claims 1, or 2, wherein said Tau-binding antibody or binding fragment thereof is a monoclonal humanized antibody.
4. A Tau-binding antibody or binding fragment thereof of any of claims 1, 2, or 3, wherein said Tau-binding antibody or binding fragment thereof binds to a phosphorylated Tau region within the amino acids 197 to 206 of SEQ ID No.: 55.
5. A Tau-binding antibody or binding fragment thereof of any of claims 1, 2, 3, or 4, wherein said Tau-binding antibody or binding fragment thereof binds to soluble forms of human Tau , paired helical filaments (PHF) of human Tau or to both soluble forms of human Tau and paired helical filaments (PHF) of human Tau .
6. An isolated nucleic acid molecule encoding the light and/or heavy chain of a Tau-binding antibody or binding fragment thereof of any of claims 1, 2, 3, 4, or 5.
7. A cloning or expression vector comprising one or more nucleic acid sequences of claim 6.

8. A host cell comprising one or more nucleic acid sequences of claim 6 or one or more cloning or expression vectors of claim 7.
9. A method of producing a Tau-binding antibody or binding fragment thereof of any of claims 1, 2, 3, 4, or 5, comprising at least the steps of
 - c) culturing a host cell of claim 8, and
 - d) isolating said Tau-binding antibody or binding fragment thereof.
10. An isolated Tau-binding antibody or binding fragment thereof of any of claims 1, 2, 3, 4, or 5, for use as a therapeutically active agent.
11. An isolated Tau-binding antibody or binding fragment thereof of any of claims 1, 2, 3, 4, or 5, for use in treating a tauopathy.
12. An isolated Tau-binding antibody or binding fragment thereof for use of claim 11, wherein said tauopathy is Alzheimer's disease or progressive supranuclear palsy.
13. An isolated Tau-binding antibody or binding fragment thereof of any of claims 1, 2, 3, 4, or 5 for use as a diagnostic agent.
14. An isolated Tau-binding antibody or binding fragment thereof of any of claims 1, 2, 3, 4, or 5 for use in diagnosing a tauopathy.
15. An isolated Tau-binding antibody or binding fragment thereof for use of claim 14, wherein said tauopathy is Alzheimer's disease or progressive supranuclear palsy.
16. Use of an isolated Tau-binding antibody or binding fragment thereof of any of claims 1, 2, 3, 4, or 5 in the manufacture of a medicament for the treatment of tauopathy.
17. The use according to claim 16, wherein said tauopathy is Alzheimer's disease or progressive supranuclear palsy.